---
title: "Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293617318.md"
description: "Johnson & Johnson released Phase 3 MonumenTAL-6 trial results for relapsed/refractory multiple myeloma. The combination of TECVAYLI and TALVEY reduced the risk of disease progression or death by 89% and mortality by 62%. Additionally, TALVEY plus pomalidomide lowered progression/death risk by 73% versus standard care. The Independent Data Monitoring Committee recommended unblinding at the first interim analysis, with results to be presented at a future medical meeting."
datetime: "2026-07-23T12:30:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293617318.md)
  - [en](https://longbridge.com/en/news/293617318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293617318.md)
---

# Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results

-   Johnson & Johnson posted a July 23, 2026 press release on Phase 3 MonumenTAL-6 results in relapsed/refractory multiple myeloma. \* TECVAYLI + TALVEY cut risk of disease progression or death by 89% (HR 0.11), risk of death by 62% (HR 0.38). \* TALVEY + pomalidomide reduced risk of progression or death by 73% (HR 0.27) versus standard of care. \* IDMC recommended unblinding at the first interim analysis; results to be presented at a future medical meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230830PR\_NEWS\_USPR\_\_\_\_\_NY09774) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial](https://longbridge.com/en/news/293623520.md)
- [J&J's Proposed $5.5 Billion Talc Settlement May "Lift Remaining Overhang" On Shares, Says Guggenheim](https://longbridge.com/en/news/294076277.md)
- [BUZZ-Street View: J&J's strongest talc settlement push yet could clear legal cloud](https://longbridge.com/en/news/294044207.md)
- [J&J names C1DO1, Curium Life Tech, iQ Surgical as Polyphonic AI Fund for Surgery cohort at SRS meeting](https://longbridge.com/en/news/293630635.md)
- [Johnson & Johnson wins FDA De Novo clearance for OTTAVA robotic surgery system in US](https://longbridge.com/en/news/293462534.md)